British Columbia's Health Ministry is limiting the sales of two more diabetes drugs to curb their off-label use for weight ...

In postmenopausal women with overweight or obesity receiving tirzepatide, use of menopausal hormone therapy (MHT) is ...

Finland is demonstrating a different approach to modern healthcare—one that prioritizes accessibility, respect, and ...

Section 2 – Product/Company Update Remote Pharmacy announces continued nationwide availability of its compounded GLP-1 formulations, including semaglutide and tirzepatide-based treatments, for ...

HealthDay News — For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction, according to a study ...

TUESDAY, July 1, 2025 (HealthDay News) — For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction, ...

A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with overweight or obesity, outperforming liraglutide and placebo. Brain ...

From 23 June 2025, Tirzepatide must be implemented in primary care. Tirzepatide represents a new therapy for weight management, but requires structured implementation, appropriate monitoring, and ...

Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss ...